✦ LIBER ✦

Everolimus Plus Exemestane in Postmenopausal Patients with HR+Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

✍ Scribed by Yardley, Denise A.; Noguchi, Shinzaburo; Pritchard, Kathleen I.; Burris, Howard A.; Baselga, José; Gnant, Michael; Hortobagyi, Gabriel N.; Campone, Mario; Pistilli, Barbara; Piccart, Martine; Melichar, Bohuslav; Petrakova, Katarina; Arena, Francis P.; Erdkamp, Frans; Harb, Wael A.; Feng, Wentao; Cahana, Ayelet; Taran, Tetiana; Lebwohl, David; Rugo, Hope S.

Book ID: 121604742
Publisher: Springer Healthcare Communications
Year: 2013
Tongue: English
Weight: 505 KB
Volume: 30
Category: Article
ISSN: 0741-238X
DOI: 10.1007/s12325-013-0060-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PO59 EFFICACY AND SAFETY OF EVEROLIMUS P

PO59 EFFICACY AND SAFETY OF EVEROLIMUS PLUS EXEMESTANE COMBINATION THERAPY VERSUS MONOTHERAPY WITH EVEROLIMUS OR CAPECITABINE IN HR+, HER2− BREAST CANCER: A MULTI-CENTER, OPEN-LABEL, PHASE 2 TRIAL BOLERO-6

✍ de Boer, Richard; Jerusalem, Guy; Hurvitz, Sara; Ejlertsen, Bent; El-Hashimy, Mo 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB

3LBA Everolimus Added to Exemestane Redu

3LBA Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial

✍ M. Gnant; G.N. Hortobagyi; H. Rugo; H.A. Burris; S. Noguchi; K.I. Pritchard; J. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Anastrozole Plus Trastuzumab Prolongs Pr

Anastrozole Plus Trastuzumab Prolongs Progression-Free Survival in Postmenopausal Patients with HER2-Positive and Hormone Receptor–Positive Metastatic Breast Cancer: A Review of the TAnDEM Study

✍ Basi, Sanraj K.; Mackey, John R. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

PCN9 VALIDITY OF PROPORTIONAL HAZARDS (P

PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY)

✍ O Sofrygin; T Delea; P Tappenden; J Karnon; MM Amonkar; M Walker 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB